Table 2.
Summary of Chemokine mRNA Expression during Type-1 (PPD) and Type-2 (SEA) Bead Granuloma Formation
| Type dominance | Chemokine | Early/late | -Fold increase over normal | Receptors |
|---|---|---|---|---|
| 1 | LIX | E | >10 | CXCR1,2 |
| 1 | MIP-2 | E | >10 | CXCR1,2 |
| 1 | KC | E | 2 to 10 | CXCR1,2 |
| 1 | MIG | E | >10 | CXCR3 |
| 1 | IP-10 | E | >10 | CXCR3 |
| 1 | MIP-1α | E | >10 | CCR1,5 |
| 1 | MIP-1β | E | 2 to 10 | CCR5 |
| 1 | Lymphotactin | L | 2 to 10 | XCR1 |
| 2 | Eotaxin | L | 2 to 10 | CCR3 |
| 2 | MCP-2 | L | >10 | CCR2,3 |
| 2 | TCA-3 | L | >10 | CCR8 |
| 2 | LARC | L | >10 | CCR6 |
| 2 | MCP-3 | L | 2 to 10 | CCR2 |
| 1 & 2 | MDC | E | 2 to 10 | CCR4 |
| 1 & 2 | MCP-1 | E | >10 | CCR2 |
| 1 & 2 | MCP-5 | E and L | >10 | CCR1,2,3 |
| 1 & 2 | C10 | L | 2 to 10 | CCR? |
| 1 & 2 | TARC | E and L | 2 to 10 | CCR7,8 |
| C | Lungkine | n/a | 1 to 2 | CXC? |
| C | SLC | n/a | 1 to 2 | CXCR3,CCR7 |
| C | ELC | n/a | 1 to 2 | CCR7 |
| C | Fractalkine | n/a | 1 to 2 | CX3CR1 |
| C | MIP-1γ | n/a | 1 to 2 | CCR1,3 |
| C | SDF-1α | n/a | 1 to 2 | CXCR4 |
C, Constitutive expression; n/a, does not apply.